A positive for triple negative.
In an earlier analysis of KEYNOTE-355, the addition of pembrolizumab to first-line chemotherapy improved progression free survival compared to chemo alone in patients with newly diagnosed, advanced triple negative breast cancer (TNBC). The treatment effect of pembrolizumab was greater as the combined positive score (CPS) increased. Here, in the first report of overall survival outcomes, the addition of pembro significantly increased median OS from 16.1 months to 23.0 months among those with a CPS ≥10. However, there was no improvement in OS in the larger groups of patients with CPS ≥1 or the overall population. In other words, pembro improves survival in those with advanced TNBC and a CPS ≥10. | Cortes, N Engl J Med 2022